Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1107 | 1051 | 1174 | 1198 | 1538 | 1888 |
Fund Return | 10.7% | 5.1% | 17.36% | 6.21% | 8.99% | 6.56% |
Place in category | 112 | 113 | 137 | 44 | 112 | 93 |
% in Category | 50 | 69 | 74 | 23 | 63 | 77 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
James Alpha Global Real Estate InvI | 205.3M | 6.29 | -3.34 | 5.14 | ||
James Alpha Global Real Estate InvA | 38.06M | 5.83 | -3.71 | 4.69 | ||
Saratoga Large Capitalization Growi | 34.19M | 30.50 | 10.12 | 15.15 | ||
Saratoga Health Biotechnology Inst | 5.87M | 8.69 | 6.69 | 5.82 | ||
Saratoga Large Capitalization Growa | 2.74M | 28.79 | 12.30 | 14.87 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Health Care Adm | 37.96B | 5.49 | 5.82 | 7.98 | ||
Fidelity Select Health Care | 10.35B | 13.38 | 2.97 | 9.10 | ||
T. Rowe Price Health Sciences | 7.86B | 10.22 | 0.91 | 9.64 | ||
Vanguard Health Care Inv | 6.88B | 5.45 | 5.77 | 7.93 | ||
Fidelity Advisor Health Care A | 6.23B | 11.89 | 2.31 | 8.23 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Regeneron Pharma | US75886F1075 | 6.03 | 712.40 | -0.60% | |
Amgen | US0311621009 | 5.05 | 262.65 | -0.20% | |
Cencora Inc | US03073E1055 | 4.67 | 226.93 | +0.15% | |
Tenet Healthcare | US88033G4073 | 4.66 | 127.97 | +0.02% | |
McKesson | US58155Q1031 | 4.48 | 576.64 | -0.31% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | BUY |
Summary | Strong Sell | Strong Sell | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review